|Bid||1.1700 x 3000|
|Ask||1.1900 x 800|
|Day's Range||1.1600 - 1.2000|
|52 Week Range||1.0200 - 2.9400|
|Beta (5Y Monthly)||0.93|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 09, 2021 - Aug 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.67|
Investors with losses are encouraged to contact the firm before August 9, 2021; click here to submit trade information LOS ANGELES, July 30, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) investors that acquired shares between March 17, 2020 to February 12, 2021. Investors have until August 9, 2021 to seek an active role in this litigation. Investors are encouraged to contact atto
NEW YORK, NY / ACCESSWIRE / July 30, 2021 / Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ:ACRX) and certain of its officers.
LOS ANGELES, CA / ACCESSWIRE / July 29, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceuticals, Inc. ('AcelRx' or 'the Company') (NASDAQ:ACRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.